Leverage appears elevated despite debt being reduced from $146.4M to zero, as total liabilities of $56.0M exceed total assets of $48.9M and the current ratio compressed from 3.71 to 1.16, suggesting a thin liquidity cushion.
Kyntra Bio, Inc. (KYNB) balance sheet — 14-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 48.62M | 99.07M | 196.51M | 331.56M | 492.83M | 474.06M | 755.11M | 702.49M | 690.01M | 748.97M | 266.52M | 200.56M | 198.24M | 143.64M | 52.8M |
| Cash & Short-Term Investments | 40.29M | 88.98M | 50.48M | 235.59M | 422.01M | 405.19M | 686.54M | 533.76M | 621.4M | 735.72M | 253.18M | 181.17M | 179.82M | 122.81M | 39.89M |
| Cash Only | 9.9M | 47.87M | 50.48M | 113.69M | 155.7M | 171.22M | 678.39M | 126.27M | 89.26M | 673.66M | 173.78M | 153.32M | 165.46M | 76.33M | 38.87M |
| Short-Term Investments | 30.39M | 41.11M | 0 | 121.9M | 266.31M | 233.97M | 8.14M | 407.49M | 532.14M | 62.06M | 79.4M | 27.85M | 14.36M | 46.48M | 1.02M |
| Accounts Receivable | 3.85M | 4.22M | 28.98M | 41.05M | 16.3M | 25.4M | 41.88M | 153.66M | 63.68M | 8.45M | 10.45M | 15.4M | 13.45M | 17.5M | 8.78M |
| Days Sales Outstanding | 300.28 | 238.95 | 357.11 | 320.16 | 42.27 | 39.4 | 86.7 | 218.6 | 109.15 | 24.55 | 21.24 | 31.09 | 35.69 | 62.5 | 48.63 |
| Inventory | 3.25M | 3.74M | 3.15M | 41.56M | 40.44M | 31.02M | 16.53M | 6.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 344.62 | 2.46K | 74 | 3.83K | 727.77 | 25.2 | 680.29 | 2.19K | - | - | - | - | - | - | - |
| Other Current Assets | 1.23M | 1.12M | 111.99M | 6.71M | 4.35M | 5.07M | 1.81M | 1.72M | 4.93M | 4.8M | 2.89M | 3.99M | 4.97M | 0 | 0 |
| Total Non-Current Assets | 231K | 20.52M | 18.02M | 91.97M | 117.26M | 299.76M | 71.73M | 154.91M | 190.58M | 149.68M | 203.04M | 270.01M | 285.29M | 153.31M | 212.78M |
| Property, Plant & Equipment | 0 | 0 | 0 | 81.37M | 100.5M | 119.39M | 63.25M | 82.34M | 127.2M | 129.48M | 123.66M | 129.02M | 132.17M | 129.9M | 123.66M |
| Fixed Asset Turnover | - | - | - | 0.58x | 1.40x | 1.97x | 2.79x | 3.12x | 1.67x | 0.97x | 1.45x | 1.40x | 1.04x | 0.79x | 0.53x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 32.2M | 20.16M | 0 | 5.29M | 9.41M | 171.62M | 2.97M | 61.12M | 55.82M | 10.51M | 71.01M | 131.72M | 144.27M | 15.36M | 81.61M |
| Other Non-Current Assets | 231K | 361K | 18.02M | 5.31M | 7.35M | 8.75M | 5.5M | 11.44M | 7.57M | 9.7M | 8.37M | 9.27M | 8.85M | 8.05M | 7.51M |
| Total Assets | 48.85M | 119.59M | 214.53M | 423.53M | 610.09M | 773.82M | 826.84M | 857.4M | 880.6M | 898.65M | 469.55M | 470.57M | 483.53M | 296.95M | 265.59M |
| Asset Turnover | 0.06x | 0.05x | 0.14x | 0.11x | 0.23x | 0.30x | 0.21x | 0.30x | 0.24x | 0.14x | 0.38x | 0.38x | 0.28x | 0.34x | 0.25x |
| Asset Growth % | -185.47% | -44.25% | -49.35% | -30.58% | -21.16% | -6.41% | -3.56% | -2.63% | -2.01% | 91.38% | - | -2.68% | 62.83% | 11.81% | - |
| Total Current Liabilities | 41.76M | 29.24M | 133.31M | 217.67M | 273.56M | 225.5M | 163.19M | 102.75M | 89.03M | 77.26M | 65.13M | 67.18M | 62.75M | 37.48M | 23.68M |
| Accounts Payable | 4.58M | 3.75M | 5.06M | 17.96M | 30.76M | 26.1M | 24.79M | 6.09M | 9.14M | 5.51M | 6.22M | 6.52M | 4.55M | 1.07M | 3.11M |
| Days Payables Outstanding | 523.97 | 2.46K | 118.78 | 1.65K | 553.58 | 21.21 | 1.02K | 1.94K | 14.14 | 10.23 | 12.13 | 11.12 | 11.02 | 4.54 | 15.28 |
| Short-Term Debt | 0 | 0 | 0 | 40K | 0 | 0 | 0 | 983K | 0 | 0 | 0 | 0 | 403K | 0 | 0 |
| Deferred Revenue (Current) | 22.58M | 5.31M | 27.29M | 12.74M | 12.74M | 19.03M | 6.55M | 490K | 13.77M | 7.97M | 7.99M | 12.73M | 9.22M | 5.74M | 2.39M |
| Other Current Liabilities | 35.59M | 3.15M | 70.29M | 152.58M | 7.25M | 4.91M | 95.53M | 63.05M | 44.69M | 17.38M | 36.68M | 34.4M | 5.16M | 2.51M | 2.43M |
| Current Ratio | 1.16x | 3.39x | 1.47x | 1.52x | 1.80x | 2.10x | 4.63x | 6.84x | 7.75x | 9.69x | 4.09x | 2.99x | 3.16x | 3.83x | 2.23x |
| Quick Ratio | 1.09x | 3.26x | 1.45x | 1.33x | 1.65x | 1.96x | 4.53x | 6.77x | 7.75x | 9.69x | 4.09x | 2.99x | 3.16x | 3.83x | 2.23x |
| Cash Conversion Cycle | 120.94 | 237.64 | 312.34 | 2.49K | 216.46 | 43.4 | -253.19 | 472.86 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 14.29M | 85.88M | 264.85M | 368.06M | 338M | 319.21M | 222.2M | 219.25M | 263.1M | 238.94M | 229.32M | 206.57M | 180.1M | 151.87M | 119.73M |
| Long-Term Debt | 0 | 0 | 73.09M | 89.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.86M | -5.81M |
| Capital Lease Obligations | 0 | 0 | 0 | 66.64M | 79.59M | 88.78M | 26.24M | 38.55M | 97.16M | 97.76M | 97.35M | 97.04M | 96.82M | 96.41M | 92.5M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.04M | 3.66M | 4.21M | 4.7M | 5.13M | 5.5M | 5.81M |
| Other Non-Current Liabilities | 14.29M | 85.62M | 77.05M | 54.17M | 72.69M | 43.63M | 57.49M | 81.25M | 29.83M | 167.19M | 25.26M | 24.39M | 22.29M | 31.1M | 12.24M |
| Total Liabilities | 56.04M | 115.12M | 398.16M | 585.73M | 611.57M | 544.71M | 385.39M | 321.99M | 352.13M | 316.2M | 294.44M | 273.75M | 242.85M | 189.35M | 143.4M |
| Total Debt | 0 | 0 | 73.09M | 170.46M | 89.89M | 99.72M | 39.76M | 51.89M | 97.16M | 97.76M | 97.35M | 97.04M | 97.22M | 96.81M | 93.23M |
| Net Debt | -9.9M | -47.87M | 22.61M | 56.77M | -65.81M | -71.5M | -638.63M | -74.38M | 7.9M | -575.89M | -76.43M | -56.28M | -68.23M | 20.48M | 54.36M |
| Debt / Equity | 0.00x | - | - | - | - | 0.44x | 0.09x | 0.10x | 0.18x | 0.17x | 0.56x | 0.49x | 0.40x | 0.90x | 0.76x |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.17x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -14.92x | -6.66x | -17.60x | -38.93x | -203.77x | -324.21x | -77.57x | -25.65x | -6.84x | -11.42x | -4.76x | -7.04x | -4.51x | -0.74x | -2.72x |
| Total Equity | 14.29M | 4.47M | -183.63M | -162.2M | -1.48M | 229.11M | 441.45M | 535.41M | 528.47M | 582.45M | 175.11M | 196.82M | 240.68M | 107.6M | 122.18M |
| Equity Growth % | 262.08% | 102.44% | -13.22% | -10859.39% | -100.65% | -48.1% | -17.55% | 1.31% | -9.27% | 232.62% | - | -18.22% | 123.67% | -11.93% | - |
| Book Value per Share | 3.53 | 1.11 | -45.89 | -41.67 | -0.40 | 62.02 | 122.82 | 154.50 | 157.17 | 199.50 | 69.77 | 3.26 | 4.19 | 2.28 | 9.28 |
| Total Shareholders' Equity | -7.19M | -30.04M | -225.6M | -204.17M | -21.45M | 209.15M | 422.18M | 516.13M | 509.2M | 563.18M | 155.84M | 177.55M | 221.41M | 79.73M | 94.48M |
| Common Stock | 41K | 1.01M | 1.01M | 988K | 942K | 929K | 914K | 877K | 854K | 825K | 637K | 620K | 590K | 132K | 132K |
| Retained Earnings | -1.71B | -1.71B | -1.89B | -1.84B | -1.56B | -1.26B | -974.01M | -784.72M | -715.83M | -595.95M | -469.74M | -408.06M | -322.28M | -262.78M | -247.84M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.21M | -2.18M | -5.73M | -6.88M | -5.72M | -4.16M | -4.5M | -747K | -2.28M | -1.79M | -960K | -1.65M | -3.15M | -3.51M | -167K |
| Minority Interest | 21.48M | 34.51M | 41.97M | 41.97M | 19.97M | 19.97M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 27.88M | 27.7M |
Quick answers to the most common questions about buying KYNB stock.
As of 2025, Kyntra Bio, Inc. (KYNB) had total assets of $119.6M including $99.1M in current assets.
Kyntra Bio, Inc. (KYNB) carries total debt of $0.0M, offset by $89.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Kyntra Bio, Inc. (KYNB) has total shareholders' equity (book value) of $-30.0M ($1.11 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Kyntra Bio, Inc. (KYNB) reported a current ratio of 3.39x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative equity and shrinking asset base
Metrics are mathematically derived from official filings.
Deepening Negative Equity Trend
Based on reported quarterly figures, KYNB's stockholders' deficit widened from $243.7M in 2024Q3 to roughly $7.2M in 2026Q3 after first narrowing, while total assets fell from $293.2M to $48.9M over the same ten-quarter window.
The shrinking asset base alongside a volatile deficit suggests the balance sheet has been contracting rather than rebuilding, with the most recent improvement in equity likely reflecting liability reduction rather than earnings strength. Retained earnings remained near negative $1.7B to $1.9B throughout, indicating the accumulated loss history has not been meaningfully reversed. Investors should monitor whether the 2026Q3 deficit narrowing persists, as the figures alone do not establish a durable repair trajectory.
Thin Cash Buffer Against Current Obligations
As reported in the balance sheets, KYNB's current ratio compressed from 3.71 in 2025Q3 to 1.16 in 2026Q3, while cash fell to $9.9M, a level that appears thin relative to total liabilities of $56.0M.
The sharp decline in cash from $118.0M to $9.9M over four quarters, combined with a current ratio that still exceeds 1.0, suggests short-term obligations are covered on paper but with limited margin for error. Cash position relative to total liabilities implies the company may depend on near-term financing or asset monetization. This warrants further investigation, since the figures do not disclose the timing or terms of current liabilities.
Debt Retired but Leverage Remains Elevated
Based on KYNB's reported figures, total debt declined from $146.4M in 2024Q2 to zero in 2026Q3, yet the debt-to-equity ratio was last reported at 1.20 in 2025Q3 and total liabilities still exceed total assets.
Debt reduction is visible in the reported figures, but total liabilities of $56.0M against assets of $48.9M indicate the company remains in a deficit position regardless of borrowings. The reduction in debt appears to have been achieved while equity deteriorated, which may point to settlement of obligations through means other than cash. The data does not disclose the mechanism, so this interpretation warrants further investigation.
Equity Deficit Driven by Accumulated Losses
According to reported balance sheets, KYNB's equity moved from a deficit of $243.7M to $7.2M, with retained earnings consistently near negative $1.7B, reflecting an accumulated loss base that dwarfs any recent equity movement.
The scale of accumulated deficit relative to current equity suggests that the recent narrowing reflects balance sheet restructuring rather than operating profitability. Stock-based compensation and share issuance data are not provided, so dilution effects cannot be assessed from the supplied figures. The equity position appears structurally weak, and further review of capital transactions is needed.
Deferred Revenue Collapse Limits Visibility
Based on reported figures, KYNB's deferred revenue fell from $155.1M in 2024Q3 to $6.2M in 2026Q3, a decline of roughly 96%, leaving little reported contractual revenue backlog to support forward expectations.
The sharp reduction in deferred revenue suggests that previously recognized or unwound contract balances have largely run off without replacement at comparable scale. This lowers the visibility investors can draw from the balance sheet regarding future recognized revenue. Remaining performance obligations are not disclosed in the supplied data, so the full forward picture cannot be established.
Headline Equity Narrowing May Mislead
As reported in the balance sheets, KYNB's deficit compression to $7.2M rests on a $1.7B accumulated loss base, so a small equity figure may reflect liability settlement rather than a repaired capital structure.
Because retained earnings sit near negative $1.7B, the near-zero equity figure is highly sensitive to small changes in liabilities or asset valuations, meaning the 2026Q3 narrowing could reverse with modest adverse movements. Given that cash fell to $9.9M and assets shrank sharply, the apparent balance sheet improvement may be a function of reduced scale rather than enhanced financial strength. Investors should treat the headline deficit reduction as analytically fragile and warrant further investigation into the composition of remaining liabilities.